Sysmex Corporation (TYO:6869)

Market Cap	1.57T
Revenue (ttm)	508.64B
Net Income (ttm)	53.67B
Shares Out	623.61M
EPS (ttm)	86.05
PE Ratio	29.31
Forward PE	26.22
Dividend	36.00 (1.43%)
Ex-Dividend Date	Sep 29, 2025

Volume	938,200
Average Volume	1,374,905
Open	2,500.00
Previous Close	2,511.50
Day's Range	2,500.00 - 2,524.50
52-Week Range	2,138.00 - 3,236.00
Beta	0.81
RSI	54.75
Earnings Date	Aug 6, 2025

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1968
• Employees: 10,533
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 6869

Financial Performance

In 2024, Sysmex's revenue was 508.64 billion, an increase of 10.21% compared to the previous year's 461.51 billion. Earnings were 53.67 billion, an increase of 8.12%.